Secukinumab (Cosentyx®) Effectiveness in Axial Spondyloarthritis and Psoriatic Arthritis Patients Using Artificial Intelligence (SpAINET): Spanish Multicenter, Retrospective, Real World Evidence Study

Sponsor
Novartis Pharmaceuticals
Study ID
NCT05677542
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • secukinumab — DRUG
    all patients who received secukinumab

Study Details

This was a multicenter, retrospective, and non-interventional study using secondary data captured in the Electronic Health Records (EHRs). The extraction of the data captured in the EHRs was performed with EHRead® by SAVANA, an innovating data-driven system based on Natural Language Processing (NLP) and big data analytics. Data was extracted and analyzed at Index Date, Follow Up, or as specified for each variable.

Key Dates

Start date
Jun 2, 2021
Status verified
Dec 2022
Primary completion
Dec 31, 2021
Completion
Dec 31, 2021

Study Design

Enrollment
758 participants (actual)

Arms

  • Arm: Axial Spondyloarthritis Patients
    Patients with Axial Spondyloarthritis
  • Arm: Psoriatic Arthritis Patients
    Patients with Psoriatic Arthritis

Primary Outcome Measure

Proportion of patients achieving disease control status at 6 months (±3 months) of secukinumab treatment [ Time Frame: month 6 ]

Related Studies